Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNXNYSE:HNGRNASDAQ:IMACNASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$29.99-1.4%$31.48$24.10▼$62.53$2.85B0.28829,790 shs532,620 shsHNGRHanger$18.72$18.70$13.42▼$22.67$732.38M1.28356,429 shsN/AIMACIMAC$0.04-5.1%$0.04$0.75▼$1.65$1.14M-0.88708,132 shs16,428 shsMLTXMoonLake Immunotherapeutics$47.29-0.2%$41.63$31.42▼$58.26$3.03B1.23381,585 shs527,462 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals-1.38%-1.67%+1.66%-13.65%-28.92%HNGRHanger0.00%0.00%0.00%0.00%0.00%IMACIMAC-4.97%-5.29%+30.30%-31.20%-98.32%MLTXMoonLake Immunotherapeutics-0.17%+8.71%+22.58%+18.64%+17.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRNXCrinetics Pharmaceuticals3.6545 of 5 stars3.50.00.03.73.32.50.0HNGRHangerN/AN/AN/AN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/AN/AN/AN/AMLTXMoonLake Immunotherapeutics1.9235 of 5 stars3.50.00.00.03.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56148.60% UpsideHNGRHanger 0.00N/AN/AN/AIMACIMAC 0.00N/AN/AN/AMLTXMoonLake Immunotherapeutics 3.00Buy$74.5057.54% UpsideCurrent Analyst Ratings BreakdownLatest HNGR, IMAC, MLTX, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025CRNXCrinetics PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.006/3/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$1.04M2,699.97N/AN/A$14.29 per share2.10HNGRHanger$1.12B0.65$1.88 per share9.98$2.85 per share6.57IMACIMAC$15.22M0.07N/AN/A$0.69 per share0.06MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)HNGRHanger$41.98M$0.9519.7115.60N/A3.17%35.72%4.00%N/AIMACIMAC-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/AMLTXMoonLake Immunotherapeutics-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)Latest HNGR, IMAC, MLTX, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AHNGRHangerN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A22.5322.53HNGRHanger3.711.230.85IMACIMAC0.011.271.27MLTXMoonLake Immunotherapeutics0.1821.1121.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%HNGRHanger79.17%IMACIMAC24.27%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals4.60%HNGRHanger4.36%IMACIMAC10.00%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21093.63 million89.32 millionOptionableHNGRHanger5,20039.12 million37.42 millionOptionableIMACIMAC10626.49 million23.84 millionNot OptionableMLTXMoonLake Immunotherapeutics264.01 million56.32 millionOptionableHNGR, IMAC, MLTX, and CRNX HeadlinesRecent News About These CompaniesMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc.June 11, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Buy" by AnalystsJune 11, 2025 | marketbeat.comCantor Fitzgerald Forecasts MLTX FY2026 EarningsJune 10, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock NewsJune 9, 2025 | gurufocus.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 7, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 3.9% - What's Next?June 6, 2025 | marketbeat.comMoonLake Immunotherapeutics is for sale? This sounds like a cry for helpJune 5, 2025 | statnews.comSMoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTXJune 5, 2025 | nasdaq.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Volume Increase - Here's WhyJune 4, 2025 | marketbeat.comMLTX Stock Gains 18% as Merck Reportedly Eyes BuyoutJune 4, 2025 | zacks.comWellington Management Group LLP Lowers Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)June 4, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)June 4, 2025 | marketbeat.comMoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma InterestJune 3, 2025 | seekingalpha.comConstellation and Meta, Merck, Snowflake: Trending TickersJune 3, 2025 | finance.yahoo.comMerck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FTJune 3, 2025 | fiercebiotech.comFMoonLake Immunotherapeutics Catapults On Rumored Merck TakeoverJune 3, 2025 | msn.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's What HappenedJune 3, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Outperform Rating from Royal Bank of CanadaJune 3, 2025 | marketbeat.comMerck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: ReportJune 3, 2025 | benzinga.comMerck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: ReportJune 3, 2025 | finance.yahoo.comMoonLake Immunotherapeutics stock surges on FT report of Merck buyout talksJune 2, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHNGR, IMAC, MLTX, and CRNX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$29.99 -0.42 (-1.38%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$30.32 +0.33 (+1.08%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Hanger NYSE:HNGRHanger, Inc. provides orthotic and prosthetic (O&P) services in the United States. It operates in two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and offers payor network contracting services to other O&P providers. The Products & Services segment engages in the distribution of various O&P parts, componentry, and devices to independent O&P providers; development of specialized rehabilitation technologies; and provision of evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2021, the company operated approximately 760 patient care clinics and 115 satellite locations in 47 states and the District of Columbia. It also distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.IMAC NASDAQ:IMAC$0.04 0.00 (-5.08%) As of 06/25/2025IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.MoonLake Immunotherapeutics NASDAQ:MLTX$47.29 -0.08 (-0.17%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$47.22 -0.06 (-0.14%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
